

Flowchart: Hypercalcaemia in Paediatric Oncology

Version:	1
Approval Committee:	Wessex PIER Regional Guideline Governance Group
Date of Approval:	tbc
Ratification Group (eg Clinical network):	Wessex Paediatric Oncology Network
Date of Ratification	2/5/18
Signature of ratifying Group Chair	Juliet Gray
Author's and job titles	Claire Fosbrook: Paediatric Oncology Pharmacist Editor: Dr Amy Mitchell Paediatric Oncology Consultant,
Date issued:	4-May-2018
Review date:	4-May-2021
Key words:	
Main areas affected:	Paediatric Oncology,
Other stakeholders consulted e.g. other clinical networks, departments	Regional oncology network, paediatric endocrinology team UHS
Summary of most recent changes (if updated guideline):	
Relevant national or international Guidance eg NICE, SIGN, BTS, BSPED	
Consultation document completed: see Appendix A	
Total number of pages:	1
Is this document to be published in any other format?	Yes available on Paediatric Oncology Extranet,
Does this document replace or revise an existing document? If so please identify here which document/s Paediatric Oncology Supportive Care Guidelines S Bevin Version 1,	

1.1 Introduction

1.2 Scope

This guideline applies to all paediatric oncology patients in the Wessex region. It does not apply to neonates on neonatal units.

1.3 Purpose

Children receiving treatment at the Southampton Paediatric Oncology Principal Treatment Centre (PTC) have open access to the designated Paediatric Oncology Ward at either the PTC or their Paediatric Oncology Shared Care Unit (POSCU) Hospital. Their parents/carers will be in possession of contact details for these wards and have been instructed to contact them for any medical problems that arise while they are receiving treatment. These Guidelines are intended for the use of the medical teams at the PTC or POSCU. If one of the Paediatric Oncology patients presents to a medical service outside of the PTC or POSCU, please contact the medical teams at the PTC or POSCU for advice.

2 Implementation

Network updated at Network meeting of changes in guideline.

3 Process for Monitoring Effectiveness

Reduced variation in practice has been shown to improve outcomes. Please detail how the impact of this guideline will be measured to demonstrate its effectiveness and identify areas for further development. Where possible this should include patient reported outcomes.

4 References: London supportive care guidelines

5 Appendices

Appendix A Paediatric Regional Guideline Consultation Documentation:

Appendix A

Paediatric Regional Guideline Consultation Documentation Paediatric Oncology Consultants (UHS):

The Wessex paediatric oncology network have agreed that new guidelines being developed by the wessex paediatric oncology supportive care guidelines working party can be ratified as follows:

All documents are edited by Dr Amy Mitchell and all are approved by at least 1 other Paediatric Oncology Consultant. Any controversial issues are brought before the MDT and final sign off is by the Network Lead Dr Juliet Gray.

On this basis the region accept the use of these guidelines for the management of their shared care paediatric oncology patients.

Name of person consulted* (print)	Signature	Date Signed
Dr Juliet Gray	Dr Juliet Gray	
Dr Gary Nicolin	Dr Gary Nicolin	3/5/18
Dr Amy Mitchell	Dr Amy Mitchell	4/5/18

* this person agrees they have read the guidelines, consulted with relevant colleagues and members of MDT, managers and patients, young people & their families as appropriate. Any queries raised during consultation and review process should be documented with responses and any changes made to guideline.

§ this can be electronic for ease

Management of Hypercalcaemia in Paediatric Oncology

